JP2012518012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518012A5 JP2012518012A5 JP2011550316A JP2011550316A JP2012518012A5 JP 2012518012 A5 JP2012518012 A5 JP 2012518012A5 JP 2011550316 A JP2011550316 A JP 2011550316A JP 2011550316 A JP2011550316 A JP 2011550316A JP 2012518012 A5 JP2012518012 A5 JP 2012518012A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticle
- lipid
- group
- nanoparticles
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 34
- 239000002105 nanoparticle Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 14
- 239000002738 chelating agent Substances 0.000 claims description 11
- 229910021645 metal ion Inorganic materials 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 229920001281 polyalkylene Polymers 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- -1 acyl-peptides Natural products 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000005298 paramagnetic effect Effects 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims description 2
- 229960005063 gadodiamide Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 229940071238 n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Drugs 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 150000008103 phosphatidic acids Chemical group 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 235000004426 flaxseed Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15245909P | 2009-02-13 | 2009-02-13 | |
| US61/152,459 | 2009-02-13 | ||
| US16298909P | 2009-03-24 | 2009-03-24 | |
| US61/162,989 | 2009-03-24 | ||
| PCT/US2010/024324 WO2010094043A2 (en) | 2009-02-13 | 2010-02-16 | Gadolinium expressed lipid nanoparticles for magnetic resonance imaging |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015229868A Division JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518012A JP2012518012A (ja) | 2012-08-09 |
| JP2012518012A5 true JP2012518012A5 (enExample) | 2013-04-04 |
| JP5847588B2 JP5847588B2 (ja) | 2016-01-27 |
Family
ID=42562321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550316A Active JP5847588B2 (ja) | 2009-02-13 | 2010-02-16 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
| JP2015229868A Active JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015229868A Active JP6072205B2 (ja) | 2009-02-13 | 2015-11-25 | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20120087857A1 (enExample) |
| EP (1) | EP2398503B1 (enExample) |
| JP (2) | JP5847588B2 (enExample) |
| CN (2) | CN106362171A (enExample) |
| WO (1) | WO2010094043A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151650A1 (en) * | 2012-04-05 | 2013-10-10 | University Of Florida Research Foundation, Inc. | Neurophilic nanoparticles |
| US20170332910A1 (en) * | 2014-11-03 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof |
| GB201509934D0 (en) | 2015-06-08 | 2015-07-22 | King S College London | Nanoparticles |
| CN107708672A (zh) * | 2015-06-15 | 2018-02-16 | 华盛顿大学 | 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法 |
| CN107412790B (zh) * | 2017-09-08 | 2019-02-22 | 丽水市中心医院 | 一种核磁共振纳米材料的制备方法 |
| WO2019211843A1 (en) * | 2018-04-30 | 2019-11-07 | Bar-Ilan University | Polymeric core-shell particles |
| US20200261605A1 (en) * | 2019-01-24 | 2020-08-20 | Alzeca Biosciences, LLC | Functionalized liposomes for imaging misfolded proteins |
| US11116854B2 (en) * | 2020-01-29 | 2021-09-14 | Texas Children's Hospital | Targeted contrast agents for MRI of amyloid deposition |
| CN113730614B (zh) * | 2021-09-09 | 2022-02-22 | 南京市第一医院 | 一种镥标记的纳米载体及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833948A (en) | 1995-06-15 | 1998-11-10 | Bracco Research S.A. | Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant |
| JP2002522514A (ja) * | 1998-08-10 | 2002-07-23 | ブラッコ・リサーチ・ソシエテ・アノニム | ポジティブｍｒｉコントラスト剤とネガティブｍｒｉコントラスト剤との組合せ |
| US20030082103A1 (en) * | 2000-10-11 | 2003-05-01 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| KR100904954B1 (ko) * | 2001-05-30 | 2009-06-26 | 더 스크립스 리서치 인스티튜트 | 핵산용 전달 시스템 |
| WO2004083902A2 (en) * | 2002-10-25 | 2004-09-30 | Georgia Tech Research Corporation | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
| EP2338525A3 (en) | 2003-07-09 | 2011-08-03 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| CN1897978B (zh) * | 2003-12-22 | 2011-11-23 | 博莱科瑞士股份有限公司 | 具有用于反差成像的活性组分的充气微囊组件 |
| CA2563619A1 (en) * | 2004-04-20 | 2005-11-03 | Emory University | Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof |
| BRPI0518952A2 (pt) * | 2004-12-17 | 2008-12-16 | Koninkl Philips Electronics Nv | mÉtodo para a produÇço de um agente de contraste marcador ou um agente terapÊutico, agentes de contraste marcadores, e, uso dos agentes de contraste marcadores ou dos agentes terapÊuticos de marcaÇço |
| US8753673B2 (en) * | 2006-05-23 | 2014-06-17 | Taiwan Liposome Co. Ltd. | Liposome composition for delivery of a therapeutic agent to eyes |
| EP2120876B1 (en) * | 2007-03-05 | 2015-03-04 | Washington University | Nanoparticle delivery systems for membrane-integrating peptides |
| KR20080094473A (ko) * | 2007-04-20 | 2008-10-23 | 한국화학연구원 | 음이온성 지질나노입자 및 이의 제조방법 |
| US20110027172A1 (en) * | 2007-12-10 | 2011-02-03 | Zhuang Wang | Drug delivery system for pharmaceuticals and radiation |
-
2010
- 2010-02-16 CN CN201610996986.1A patent/CN106362171A/zh active Pending
- 2010-02-16 JP JP2011550316A patent/JP5847588B2/ja active Active
- 2010-02-16 WO PCT/US2010/024324 patent/WO2010094043A2/en not_active Ceased
- 2010-02-16 CN CN2010800105605A patent/CN102341126A/zh active Pending
- 2010-02-16 EP EP10741884.0A patent/EP2398503B1/en active Active
-
2011
- 2011-08-11 US US13/208,100 patent/US20120087857A1/en not_active Abandoned
-
2015
- 2015-11-25 JP JP2015229868A patent/JP6072205B2/ja active Active
-
2016
- 2016-12-05 US US15/369,661 patent/US11207430B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Diagnostic imaging and therapeutic application of nanoparticles targeting the liver | |
| JP2012518012A5 (enExample) | ||
| Kuai et al. | High-density lipoproteins: nature’s multifunctional nanoparticles | |
| JP6072205B2 (ja) | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 | |
| US20130045161A1 (en) | Methods and compositions for targeted imaging | |
| JP2016094425A5 (enExample) | ||
| JP4332507B2 (ja) | 医薬組成物 | |
| ES2848209T3 (es) | Direccionamiento específico de célula mediante sistemas portadores nanoestructurados | |
| JP2014526442A (ja) | アポトーシス−ターゲティングナノ粒子 | |
| JPH09512265A (ja) | コントラスト剤 | |
| JPH10507172A (ja) | リポソーム剤 | |
| PT1863448E (pt) | Novas composições de lipossomas | |
| CN103860468B (zh) | 一种t7肽修饰的zl006长循环脂质体及其制备方法 | |
| JP2015502946A5 (enExample) | ||
| JP2024037760A (ja) | アミロイド沈着のｍｒｉのための標的造影剤 | |
| US6562371B1 (en) | Liposomes | |
| WO2021245547A1 (en) | Liposomal system with killer tnf-apoptosis induced ligand (killertrail), pro-apoptotic-directing | |
| US10894098B2 (en) | Methods and compositions for targeted imaging | |
| JP2006519262A (ja) | リポソームにより誘導される補体活性化の減少のためのリポソーム組成物 | |
| JP4827277B2 (ja) | リポソーム | |
| JP2019512484A (ja) | 骨髄、細網内皮系、および／またはリンパ節を標的にする放射標識リポソームならびにその診断用および治療用使用の方法 | |
| US20140363378A1 (en) | Self-assembling molecules that accumulate in acidic tumor microenvironments | |
| CN115260304A (zh) | 一种基于脂质的蛋白降解工具、应用及其制备方法 | |
| JP5936002B2 (ja) | 組合わせ医薬製剤 | |
| CA3192148A1 (en) | Galactosylated dendrimers for targeted intracellular delivery to hepatocytes |